Presbyopia is a natural, age-related condition affecting 128 million worldwide, often addressed with traditional solutions like reading glasses or progressive lenses. However, a groundbreaking alternative is emerging: QLOSI, a new presbyopia treatment featuring a 0.4% pilocarpine hydrochloride ophthalmic solution. During a recent Defocus Media podcast episode, Dr. Jennifer  Lyerly and Dr. Darryl Glover interviewed Dr. Jade Coats and explored the potential of QLOSI  to transform presbyopia management. This article delves into the key insights from the interview, focusing on how this innovative presbyopia solution offers a promising new approach for eye care professionals.  

Many presbyopes remain unmotivated to adopt traditional solutions like progressives or multifocal lenses. As Dr. Lyerly noted, 62% of presbyopes still use over-the-counter readers,  highlighting a gap in motivation and satisfaction.  

QLOSI introduces a new paradigm by serving as an adjunctive option rather than a replacement for glasses or contact lenses. Its lower concentration of pilocarpine minimizes side effects while maximizing efficacy, making it a more attractive option for patients reluctant to commit to traditional solutions.  

QLOSI provides eye care professionals with a customizable treatment option that aligns with patients’ lifestyles. As Dr. Jade Coats pointed out, offering an alternative like QLOSI can empower patients with choices beyond traditional eyewear.  

Educating patients about the science behind QLOSI—from its miotic action to its EyeQ Formulation can help eye care professionals build trust and confidence. Highlighting the mechanism of action, such as the pinhole effect created by pupillary constriction, simplifies complex information for patients.  

According to clinical trials, the ideal candidates for QLOSI are patients aged 45 to 55 with mild  to moderate presbyopia. Educating these patients about the benefits of a presbyopia eye drop  over traditional options can significantly improve adoption rates.  

1. Patient Education: Use simple analogies, such as the pinhole effect, to explain the  mechanism of action.  

2. Additional Guidance: Recommend that patients take QLOSI two times a day for the first  week as they learn their new near (Neuroadapt – similar to guidance for those with  progressives of MFCLs)  

3. Follow-Up: Schedule follow-ups within two weeks to assess adaptation and  effectiveness, as clinical trials indicate that neuroadaptation improves efficacy over  time.  

QLOSI with EyeQ Formulation is a significant leap forward in presbyopia management by  offering the lowest effective pilocarpine solution that enhances near vision without sacrificing  distance vision, giving your patients Qlosi Clear Moments. Its unique EyeQ Formulation—including a  near-neutral pH, preservative-free composition, and the addition of hyaluronic and HPMC  lubricating agents for comfort—sets it apart from previous treatments. As eye care professionals  look to adopt cutting-edge solutions, integrating QLOSI into their practices could redefine  presbyopia management for the modern patient.

Call to Action: Discover how QLOSI can transform your practice. Subscribe to our newsletter  for the latest updates on presbyopia management and innovative treatment, or visit  www.qlosiECP.com for more information.

INDICATION

QLOSI is a cholinergic agonist indicated for the treatment of presbyopia in adults.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
Hypersensitivity

WARNINGS AND PRECAUTIONS
Advise patients to not drive or operate machinery if vision is not clear (e.g., blurred vision). Exercise caution in night driving and other hazardous occupations in poor illumination.

Rare cases of retinal detachment have been reported with miotics. Examination of the retina is advised in all patients prior to initiation of therapy. Advise patients to seek immediate medical care with sudden onset of flashes of lights, floaters, or vision loss.

QLOSI is not recommended to be used when iritis is present.

QLOSI should not be administered while wearing contact lenses. Remove lenses prior to the installation of QLOSI and wait 10 minutes before reinsertion.

Avoid touching the tip of the vial to the eye or any other surface.

ADVERSE REACTIONS
The most common adverse reactions (5% to 8%) are instillation site pain and headaches.